适应症: 靶点:PORCN 是否上市:临床中 研发公司:(丹麦) 说明书: 简介(概括) 详细说明书 临床指南 基因与耐药 副作用与并发症 药品百科 药品概述 LGK-974是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路,在TM3细胞中IC50为0.4 nM。 简要说明书 临床招募...
LGK974 LGK974(LGK974) 药物类型: 适应症: 靶点:PORCN 是否上市:临床中 研发公司:(丹麦) 说明书: 简介(概括) 详细说明书 临床指南 基因与耐药 副作用与并发症 药品百科
LGK974 LGK974 (LGK974) 药物类型: 适应症: 靶点:PORCN 是否上市:临床中 研发公司:(丹麦) 说明书:简介(概括) 详细说明书 临床指南 基因与耐药 副作用与并发症 药品百科 LGK974副作用与并发症 LGK974相关基因检测 肿瘤血液962基因检测升级版 基于新一代高通量测序(NGS)技术,一次性检测962个肿瘤...
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10; 110 (50) :20224-9. [2]. Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18; 545 (7654) ...
ReferencesLiu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. PMID: 24277854. Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency...
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25. PubMed PMID: 24277854; PubMed Central PMCID: PMC3864356.2: Jiang X, Hao HX, Growney JD, Woolfenden ...
[1].Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. [2].Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May ...
The porcupine inhibitor LGK974, a novel orally bioavailable cancer therapeutic in Phase I clinical trials, induces potent Wnt signaling inhibition and leads to suppressed growth and progression of multiple types of cancers. The clinical use of LGK974, however, is limited in part due to its low ...
It has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck. 细胞实验 Cells are plated in growth medium in a 96-well plate at a density of 6,000–12,000 cells per well and treated with DMSO or 1 μM LGK974. After 3 d...
LGK974 LGK974(LGK974) 药物类型: 适应症: 靶点:PORCN 是否上市:临床中 研发公司:(丹麦) 说明书: 简介(概括) 详细说明书 临床指南 基因与耐药 副作用与并发症 药品百科